Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, Phillips MF, Bhatia J, Levine DA, Aghajanian C, Offit K, Barakat RR, Spriggs DR, Kauff ND.
Cancer. 2011 Dec 2. doi: 10.1002/cncr.26655. [Epub ahead of print]
Related citations
Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study.
Trivers KF, Baldwin LM, Miller JW, Matthews B, Andrilla CH, Lishner DM, Goff BA.
Cancer. 2011 Dec 1;117(23):5334-43. doi: 10.1002/cncr.26166. Epub 2011 Jul 25.
Which is the best foot to put forward in recurrent ovarian cancer?
Rose PG.
Cancer. 2011 Nov 9. doi: 10.1002/cncr.26615. [Epub ahead of print] No abstract available.
A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Secord AA, Berchuck A, Higgins RV, Nycum LR, Kohler MF, Puls LE, Holloway RW, Lewandowski GS, Valea FA, Havrilesky LJ.
Cancer. 2011 Nov 9. doi: 10.1002/cncr.26610. [Epub ahead of print]
Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.
Hensley ML, Kravetz S, Jia X, Iasonos A, Tew W, Pereira L, Sabbatini P, Whalen C, Aghajanian CA, Zarwan C, Berlin S.
Cancer. 2012 May 1;118(9):2403-10. doi: 10.1002/cncr.26569. Epub 2011 Sep 20.
Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome.
Kim G, Davidson B, Henning R, Wang J, Yu M, Annunziata C, Hetland T, Kohn EC.
Cancer. 2012 Mar 15;118(6):1543-53. doi: 10.1002/cncr.26449. Epub 2011 Aug 25.
Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study.
McGonigle KF, Muntz HG, Vuky J, Paley PJ, Veljovich DS, Greer BE, Goff BA, Gray HJ, Malpass TW.
Cancer. 2011 Aug 15;117(16):3731-40. doi: 10.1002/cncr.25967. Epub 2011 Feb 24.
ASCO highlights new findings on cancer screening. Discoveries connected to ovarian, cervical, and prostate cancers.
Printz C.
Cancer. 2011 Aug 15;117(16):3627-9. doi: 10.1002/cncr.26399. No abstract available.
Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Fleming ND, Agadjanian H, Nassanian H, Miller CW, Orsulic S, Karlan BY, Walsh CS.
Cancer. 2012 Feb 1;118(3):689-97. doi: 10.1002/cncr.26329. Epub 2011 Jul 12.
Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Moore LE, Pfeiffer RM, Zhang Z, Lu KH, Fung ET, Bast RC Jr.
Cancer. 2012 Jan 1;118(1):91-100. doi: 10.1002/cncr.26241. Epub 2011 Jun 29.
Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
Casagrande F, Cocco E, Bellone S, Richter CE, Bellone M, Todeschini P, Siegel E, Varughese J, Arin-Silasi D, Azodi M, Rutherford TJ, Pecorelli S, Schwartz PE, Santin AD.
Cancer. 2011 Dec 15;117(24):5519-28. doi: 10.1002/cncr.26215. Epub 2011 Jun 20.
Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma.
Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, Lacour RA, Johnson KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC.
Cancer. 2011 Jun 15;117(12):2659-67. doi: 10.1002/cncr.25820. Epub 2010 Dec 29.
Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
Havrilesky LJ, Pokrzywinski R, Revicki D, Higgins RV, Nycum LR, Kohler MF, Berchuck A, Myers ER, Secord AA.
Cancer. 2012 Jan 15;118(2):386-91. doi: 10.1002/cncr.26199. Epub 2011 May 19.
Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer.
Choi CH, Lee YY, Song TJ, Park HS, Kim MK, Kim TJ, Lee JW, Lee JH, Bae DS, Kim BG.
Cancer. 2011 May 15;117(10):2104-11. doi: 10.1002/cncr.25710. Epub 2010 Nov 29.
KIT gene mutation and amplification in dysgerminoma of the ovary.
Cheng L, Roth LM, Zhang S, Wang M, Morton MJ, Zheng W, Abdul Karim FW, Montironi R, Lopez-Beltran A.
Cancer. 2011 May 15;117(10):2096-103. doi: 10.1002/cncr.25794. Epub 2010 Nov 30.
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC Jr.
Cancer. 2011 Apr 15;117(8):1661-9. doi: 10.1002/cncr.25701. Epub 2010 Nov 8.
Early detection of ovarian cancer: if only we had a "Pap smear" for this disease.
Bell JG.
Cancer. 2011 Oct 1;117(19):4340-2. doi: 10.1002/cncr.26025. Epub 2011 Apr 4. No abstract available.
How are symptoms of ovarian cancer managed? A study of primary care physicians.
Goff BA, Matthews B, Andrilla CH, Miller JW, Trivers KF, Berry D, Lishner DM, Baldwin LM.
Cancer. 2011 Oct 1;117(19):4414-23. doi: 10.1002/cncr.26035. Epub 2011 Mar 16.
Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA, Bast RC Jr.
Cancer. 2011 Oct 1;117(19):4424-38.
The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival.
Cantrell LA, Westin SN, Van Le L.
Cancer. 2011 Mar 15;117(6):1220-6. doi: 10.1002/cncr.25590. Epub 2010 Nov 8.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on